Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of BlueLinx Holdings Inc.

FT is investigating potential claims on behalf of shareholders of BlueLinx Holdings Inc. (“BlueLinx” or the “Company”) (NYSE:BXC) concerning the proposed purchase of the Company’s publicly held shares by its controlling shareholder, Cerberus ABP Investor LLC (“Cerberus ABP”), for $3.40 in cash per share. That price implies a total value for the Company of approximately $111.1 million.

The investigation is focused on the potential unfairness of the price to BlueLinx’s shareholders and the potential conflicts of interest among BlueLinx Board members. According to Yahoo! Finance, at least one analyst has set a target price of $5.00 for BlueLinx stock, and the Company traded at $6.32 on April 26, 2010—nearly three dollars more than the tender offer price. In addition to the insufficiency of the consideration offered, this investigation concerns the conduct of the Company’s controlling shareholder Cerberus ABP, which holds over 55% of the Company’s outstanding shares. Five members of the current board of BlueLinx are current or former employees of, or advisors to, Cerberus ABP’s parent company Cerberus.

If you are interested in discussing your rights as a BlueLinx shareholder, or have information relating to this investigation, please contact Finkelstein Thompson's Washington, DC offices at (877) 337-1050 or by email at This email address is being protected from spam bots, you need Javascript enabled to view it .